We first compared therapy responses by re-inoculating each tumor cell line into naïve mice and administering combination therapy including gemcitabine, nab-paclitaxel, agonistic anti-CD40 Ab, anti-CTLA-4 Ab, and anti-PD-1 Ab (GAFCP). Here, CD40 is linked to neoplasm.